Operational Costs Compared: SG&A Analysis of Amgen Inc. and Bristol-Myers Squibb Company

A Decade of SG&A Trends: Amgen Inc. vs. Bristol-Myers Squibb

In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, Amgen Inc. and Bristol-Myers Squibb Company have showcased distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amgen's SG&A expenses grew by approximately 31%, peaking in 2023. In contrast, Bristol-Myers Squibb experienced a more volatile trajectory, with a notable 72% increase from 2018 to 2020, reflecting strategic shifts and market adaptations.

Key Insights

• Amgen Inc.: Steady growth with a focus on consistent operational management.
• Bristol-Myers Squibb: Significant fluctuations, highlighting periods of aggressive expansion and restructuring.

These trends underscore the strategic priorities of each company, offering a window into their operational strategies and market positioning. As the pharmaceutical landscape continues to shift, understanding these financial dynamics is crucial for investors and industry analysts alike.